Treanda Related Clinical Trials
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma [Recruiting]
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [Recruiting]
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma [Recruiting]
PH2 Trial in Patietns With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab [Not yet recruiting]
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [Recruiting]
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia [Recruiting]
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combinaton of Bendamustine and Ofatumumab [Recruiting]
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia [Recruiting]
Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome [Recruiting]
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma [Recruiting]
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) [Recruiting]
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma [Recruiting]
MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Recruiting]
Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies [Recruiting]
Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas [Recruiting]
Open Trial of Bendamustine HCL in Women With Advanced Ovarian Cancer [Recruiting]
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Advanced Lymphoma, Multiple Myeloma, or Solid Tumors [Recruiting]
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Recruiting]
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas [Recruiting]
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors [Recruiting]
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Recruiting]
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Not yet recruiting]
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) [Recruiting]
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors [Recruiting]
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy [Recruiting]
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) [Recruiting]
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine [Recruiting]
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Recruiting]
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma [Recruiting]
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Bendamustine in Acute Leukemia and MDS [Recruiting]
Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy [Recruiting]
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. [Not yet recruiting]
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Recruiting]
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma [Recruiting]
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma [Recruiting]
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) [Recruiting]
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer [Recruiting]
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [Recruiting]
Bendamustine in Treating Patients With Recurrent or Progressive Anaplastic Glioma or Glioblastoma Multiforme [Recruiting]
Bendamustine and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Recruiting]
Fludarabine, Cyclophosphamide, and Rituximab or Bendamustine and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [Recruiting]
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma [Recruiting]
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia [Recruiting]
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL [Recruiting]
A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Recruiting]
|
